<div id="readability-page-1"><p>In a report released yesterday, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Eton Pharmaceuticals, with a price target of <span id="expert-recommendation-target">$52.00</span>. The company’s shares closed yesterday at $29.71.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Ramakanth is a 5-star analyst with an average return of <span>18.9%</span> and a 43.31% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Corcept Therapeutics, and Evotec AG.</p> <p>Eton Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $41.00, a 38.00% upside from current levels. In a report released on May 4, Craig-Hallum also reiterated a Buy rating on the stock with a $40.00 price target.</p></div>

ETON

<p>H.C. Wainwright analyst Swayampakula Ramakanth has maintained a Buy rating on Eton Pharmaceuticals (ETON) with a price target of $52.00, while the stock closed at $29.71. Ramakanth, a 5-star analyst, has an average return of 18.9% and a 43.31% success rate. Eton has a Strong Buy consensus with a price target of $41.00, indicating a 38% upside. Craig-Hallum also reiterated a Buy rating with a $40.00 target.</p>

Tip Ranks

Eton Pharmaceuticals

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares Biotechnology ETF

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VG Health

Mirum Pharmaceuticals

Corcept Therap

Evotec SE

H.C. Wainwright Remains a Buy on Eton Pharmaceuticals (ETON)